

SCORE Search Results Details for Application 10679201 and Search Result us-10-679-201-6.rag.

[Score Home Page](#) [Retrieve Application List](#) [SCORE System Overview](#) [SCORE FAQ](#) [Comments / Suggestions](#)

This page gives you Search Results detail for the Application 10679201 and Search Result us-10-679-201-6.rag.

[start](#)

[Go Back to previous page](#)

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 11, 2006, 22:00:08 ; Search time 187 Seconds
(without alignments)
512.217 Million cell updates/sec

Title: US-10-679-201-6
Perfect score: 1165
Sequence: 1 MSFVGENSEGVKMGSEDWEKD.....IEFSFQPVCKAEMSPSEVSD 218

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_21:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	1165	100.0	218	3 AAY91885	Aay91885 Primate i
2	1165	100.0	218	4 AAB47186	Aab47186 IL-1 rela
3	1165	100.0	218	4 AAG68116	Aag68116 Human int
4	1165	100.0	218	8 ADJ88306	Adj88306 Human int

5	1165	100.0	218	8	ADL15868	Adl15868	Human	int
6	1165	100.0	218	8	ADN41836	Adn41836	Amino	aci
7	1165	100.0	218	8	ADO04679	Ado04679	Human	int
8	1161	99.7	218	3	AA95299	Aay95299	Human	int
9	1154	99.1	218	3	AA70927	Aay70927	Human	zil
10	1154	99.1	218	3	AA96940	Aay96940	Human	IL-
11	1154	99.1	218	3	AAB28266	Aab28266	Human	int
12	1154	99.1	218	4	AAB85136	Aab85136	Interleuk	
13	1154	99.1	218	8	ADN05012	Adn05012	Antipsori	
14	1151	98.8	218	3	AA71084	Aay71084	Human	zil
15	1151	98.8	218	7	ADH89067	Adh89067	Human	zil
16	1150	98.7	218	3	AA70933	Aay70933	Human	zil
17	1150	98.7	218	7	ADH89075	Adh89075	Human	zil
18	1138	97.7	218	3	AA70931	Aay70931	Human	zil
19	1138	97.7	218	7	ADH89072	Adh89072	Human	zil
20	1116	95.8	218	3	AA91884	Aay91884	Primate	i
21	1116	95.8	218	8	ADJ88304	Adj88304	Human	int
22	1116	95.8	218	8	ADL15866	Adl15866	Human	int
23	1116	95.8	218	8	ADO04677	Ado04677	Human	int
24	1110	95.3	207	3	AA96938	Aay96938	Human	IL-
25	1046	89.8	198	4	AAB85138	Aab85138	Interleuk	
26	1034	88.8	218	3	AA70928	Aay70928	Human	zil
27	1034	88.8	218	7	ADH89068	Adh89068	Human	zil
28	1026.5	88.1	197	3	AA95300	Aay95300	Human	int
29	919	78.9	176	4	AAB48081	Aab48081	Human	ext
30	919	78.9	176	8	ADL66905	Adl66905	Human	ext
31	909	78.0	178	2	AAW93057	Aaw93057	Human	Tan
32	895	76.8	192	3	AA95297	Aay95297	Human	int
33	895	76.8	192	8	ADN05880	Adn05880	Antipsori	
34	895	76.8	203	3	AA96933	Aay96933	Human	IL-
35	885.5	76.0	193	3	AA96934	Aay96934	Processed	
36	885.5	76.0	193	4	AAB87596	Aab87596	Human	PRO
37	885.5	76.0	193	5	ABG95921	Abg95921	Human	sec
38	885.5	76.0	193	6	ABU90946	Abu90946	Novel	hum
39	885.5	76.0	193	6	ABO34005	Abo34005	Human	sec
40	885.5	76.0	193	6	ABU72022	Abu72022	Novel	hum
41	885.5	76.0	193	6	ABU71576	Abu71576	Human	sec
42	885.5	76.0	193	6	ABU91030	Abu91030	Human	PRO
43	885.5	76.0	193	6	ABO27351	Abo27351	Human	sec
44	885.5	76.0	193	6	ABU92546	Abu92546	Human	sec
45	885.5	76.0	193	6	ABU81216	Abu81216	Human	sec

ALIGNMENTS

RESULT 1

AA91885

ID AAY91885 standard; protein; 218 AA.

XX

AC AAY91885;

XX

DT 19-JUL-2000 (first entry)

XX

DE Primate interleukin-1 like molecule (IL-1-zeta) alternative sequence.

XX

KW Primate; interleukin-1 like; IL-1-zeta; systemic inflammation; fever;

KW hypoglycemia; plasma iron; plasma zinc; acute liver response;

KW plasma copper.

XX

OS Mammalia.

XX

FH Key Location/Qualifiers

FT Domain 58. .64

FT /label= beta_strand_1

FT Domain 69. .74
FT /label= beta_strand_2
FT Domain 76. .80
FT /label= beta_strand_3
FT Domain 91. .96
FT /label= beta_strand_4
FT Binding-site 100. .106
FT /note= "forms a loop which is part of a primary binding
FT segment to the IL-1 receptor type"
FT Domain 107. .113
FT /label= beta_strand_5
FT Domain 118. .126
FT /label= beta_strand_6
FT Domain 131. .136
FT /label= beta_strand_7
FT Domain 154. .161
FT /label= beta_strand_8
FT Domain 163. .169
FT /label= beta_strand_9
FT Domain 176. .180
FT /label= beta_strand_10
FT Domain 185. .204
FT /label= beta_strand_11
FT Domain 201. .204
FT /label= beta_strand_12
XX
PN WO200017363-A2.
XX
PD 30-MAR-2000.
XX
PF 17-SEP-1999; 99WO-US020868.
XX
PR 18-SEP-1998; 98US-00156966.
XX
PA (SCHE) SCHERING CORP.
XX
PI Timans JC;
XX
DR WPI; 2000-283588/24.
DR N-PSDB; AAA08513.
XX
PT New mammalian interleukin 1 like molecule, designated IL-1-zeta, useful
PT for diagnostic and therapeutic purposes, comprises a 128 amino acid
PT sequence.
XX
PS Claim 1; Page 103-104; 110pp; English.
XX
CC The present sequence is an alternative primate interleukin-1 like
CC molecule, designated IL-1-zeta. The 12 beta strands, indicated in the
CC features table, fold into a beta-trefoil fold. The specification claims
CC an isolated or recombinant polypeptide that: (a) specifically binds
CC polyclonal antibodies generated against at least a 12 consecutive amino
CC acid segment of IL-1-zeta (see AAY91884) or its allelic variant (see
CC AAY91885); and (b) comprises at least one sequence selected from:
CC AAY91886-903 or AAY91904-06. The preferred 12 consecutive amino acid
CC segment is chosen from AAY91907-18 or AAY91919-21. IL-1-zeta is likely to
CC play a role in systemic inflammatory reactions, such as fever,
CC hypoglycemia, reduced plasma iron and zinc, the acute response of the
CC liver, and increase plasma copper. IL-1-zeta binding compounds
CC (comprising antigen binding sites) and IL-1-zeta polypeptides are also
CC useful for both diagnostic and therapeutic purposes
XX
SQ Sequence 218 AA;

Query Match 100.0%; Score 1165; DB 3; Length 218;

Best Local Similarity 100.0%; Pred. No. 2.2e-117;
Matches 218; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MSFVGENSEGVKMGSEDWEKDEPQCCLLEDAVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MSFVGENSEGVKMGSEDWEKDEPQCCLLEDAVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60

Qy     61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120

Qy    121 YCDKDKGQSHPSLQLKKEKLMKLAQKESARRPFIFYRAQVGSWNMLESAHPGWFICTS 180
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 YCDKDKGQSHPSLQLKKEKLMKLAQKESARRPFIFYRAQVGSWNMLESAHPGWFICTS 180

Qy    181 CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD 218
      ||||||||||||||||||||||||||||||||||||||||
Db    181 CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD 218
```

RESULT 2

AAB47186

ID AAB47186 standard; protein; 218 AA.

XX

AC AAB47186;

XX

DT 29-JUN-2001 (first entry)

XX

DE IL-1 related polypeptide.

XX

KW Interleukin-1-related polypeptide; HPB-MLT cell; T-cell; inhibition;
KW natural killer activity; immune system; gene therapy; immunodeficiency.

XX

OS Homo sapiens.

XX

PN EP1092773-A2.

XX

PD 18-APR-2001.

XX

PF 11-OCT-2000; 2000EP-00308948.

XX

PR 15-OCT-1999; 99JP-00294493.

XX

PA (HAYB) HAYASHIBARA SEIBUTSU KAGAKU.

XX

PI Ushio S, Nukada Y, Yamamoto K, Kurimoto M;

XX

DR WPI; 2001-275206/29.

DR

N-PSDB; AAC85680.

XX

PT New human interleukin-1-related polypeptide and polynucleotide, useful
PT for gene therapy and in developing drugs as regulators of natural killer
PT activity, are capable of inhibiting natural killer activity.

XX

PS Claim 1; Page 12; 15pp; English.

XX

CC This sequence represents an interleukin-1 (IL-1)-related polypeptide. IL-
CC 1 related polypeptide was isolated from HPB-MLT cells, FERM-BP-2430, an
CC established human T-cell line. IL-1 related polypeptide is useful for
CC inhibiting natural killer (NK) activity, which is related to the immune
CC system of mammals. The DNA encoding the IL-1 related polypeptide is
CC useful in gene therapy of patients in need of NK activity inhibition and
CC others suffering from immunodeficiency

XX

SQ Sequence 218 AA;

Query Match 100.0%; Score 1165; DB 4; Length 218;
Best Local Similarity 100.0%; Pred. No. 2.2e-117;
Matches 218; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MSFVGENSGVKMGSEDWEKDEPQCCLDPVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60
      |||
Db      1 MSFVGENSGVKMGSEDWEKDEPQCCLDPVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60

Qy     61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120
      |||
Db     61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120

Qy    121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS 180
      |||
Db    121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS 180

Qy    181 CNCNEPVGVTDFENRKHIEFSFQPVCKAEMSPSEVSD 218
      |||
Db    181 CNCNEPVGVTDFENRKHIEFSFQPVCKAEMSPSEVSD 218
```

RESULT 3

AAG68116

ID AAG68116 standard; protein; 218 AA.

XX

AC AAG68116;

XX

DT 22-JAN-2002 (first entry)

XX

DE Human interleukin 1 family protein SEQ ID NO:2.

XX

KW Human; interleukin 1; IL-1; growth factor; Tango-77; diagnosis;
KW identification.

XX

OS Homo sapiens.

XX

PN JP2001231578-A.

XX

PD 28-AUG-2001.

XX

PF 07-DEC-2000; 2000JP-00372864.

XX

PR 09-DEC-1999; 99JP-00349780.

XX

PA (KYOW) KYOWA HAKKO KOGYO KK.

XX

DR WPI; 2001-609968/70.

DR

N-PSDB; AAI71179.

XX

PT An IL-1 family protein, used for the development of diagnostic and
PT treatment agents.

XX

PS Claim 1; Page 30; 38pp; Japanese.

XX

CC The present sequence represents a human interleukin 1 (IL-1) family
CC protein having a combining affinity to a receptor of a protein of human
CC IL-1 family higher than Tango-77. The protein is useful for the
CC development of diagnostic, treating and/or preventive agents for various
CC diseases

XX

SQ Sequence 218 AA;

Query Match 100.0%; Score 1165; DB 4; Length 218;
Best Local Similarity 100.0%; Pred. No. 2.2e-117;

[illegible]

PT useful for diagnosing, preventing or treating diseases associated with

PT abnormal expression of interleukin, e.g. inflammation, infection or
PT cancer.
XX
PS Claim 2; SEQ ID NO 4; 36pp; English.
XX
CC The invention relates to an isolated or recombinant nucleic acid encoding
CC interleukin-1zeta polypeptide. The invention is useful in gene therapy.
CC The composition and methods are useful in diagnosing or treating
CC degenerative or abnormal conditions which directly or indirectly involve
CC development, differentiation or function, e.g. of the immune system
CC and/or haematopoietic cells. The invention may also be used for
CC preventing or treating other diseases or disorders associated with
CC abnormal expression or triggering of response to the interleukin, such as
CC inflammatory disorders, infection, allergies or cancer. The present
CC sequence is human interleukin-1zeta variant.
XX
SQ Sequence 218 AA;

Query Match 100.0%; Score 1165; DB 8; Length 218;
Best Local Similarity 100.0%; Pred. No. 2.2e-117;
Matches 218; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1 MSFVGENSGVKMGSEDEWKDEPQCCLLEDAVSPLPEPGPSLPAMNFVHTSPKVKNLNPKKF	60
Db	1 MSFVGENSGVKMGSEDEWKDEPQCCLLEDAVSPLPEPGPSLPAMNFVHTSPKVKNLNPKKF	60
Qy	61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSASAEGKSPIILGVSKGEFCL	120
Db	61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSASAEGKSPIILGVSKGEFCL	120
Qy	121 YCDKDKGQSHPSLQLKKEKLMKLAAQESARRPFIFYRAQVGSWNMLESAAHPGWFICTS	180
Db	121 YCDKDKGQSHPSLQLKKEKLMKLAAQESARRPFIFYRAQVGSWNMLESAAHPGWFICTS	180
Qy	181 CNCNEPVGVTDKFENRKHIEFSFPVCKAEMSPSEVSD	218
Db	181 CNCNEPVGVTDKFENRKHIEFSFPVCKAEMSPSEVSD	218

```

RESULT 5
ADL15868
ID    ADL15868 standard; protein; 218 AA.
XX
AC    ADL15868;
XX
DT    01-JUL-2004   (first entry)
XX
DE    Human interleukin 1 zeta (IL-1zeta) seqid 4.
XX
KW    antiinflammatory; interleukin 1 zeta; IL-1 zeta; immunogen;
KW    antisera production; antibody production; anti-inflammatory; human.
XX
OS    Homo sapiens.
XX
PN    US2004068099-A1.
XX
PD    08-APR-2004.
XX
PF    27-OCT-2003; 2003US-00695195.
XX
PR    18-SEP-1998;    98US-0100948P.
PR    17-SEP-1999;    99US-00398412.
XX
PA    (TIMA/) TIMANS J C.
XX

```

Query Match 100.0%; Score 1165; DB 8; Length 218;
Best Local Similarity 100.0%; Pred. No. 2.2e-117;
Matches 218; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

RESULT 6
ADN41836
ID      ADN41836 standard; protein; 218 AA.
XX
AC      ADN41836;
XX
DT      15-JUL-2004 (first entry)

```

Query Match 100.0%; Score 1165; DB 8; Length 218;
Best Local Similarity 100.0%; Pred. No. 2.2e-117;
Matches 218; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

http://es/ScoreAccessWeb/GetItem.action?AppId=10679201&seqId=512138&ItemName=us-10-679-201... 5/12/2006

|||||
Db 181 CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD 218

RESULT 7

ADO04679

ID ADO04679 standard; protein; 218 AA.

XX

AC ADO04679;

XX

DT 29-JUL-2004 (first entry)

XX

DE Human interleukin-1 zeta variant.

XX

KW Interleukin-1 zeta variant; inflammatory reaction; immune system;

KW IL-1 zeta; immunological disorder; human.

XX

OS Homo sapiens.

XX

PN US2004087766-A1.

XX

PD 06-MAY-2004.

XX

PF 27-OCT-2003; 2003US-00694978.

XX

PR 18-SEP-1998; 98US-0100948P.

PR 17-SEP-1999; 99US-00398412.

XX

PA (TIMA/) TIMANS J C.

XX

PI Timans JC;

XX

DR WPI; 2004-374758/35.

DR N-PSDB; ADO04678.

XX

PT New isolated or recombinant interleukin-1 zeta polypeptide and related
PT reagents such as antibodies, useful for treating inflammatory disease and
PT as probes for diagnosing immunological disorders.

XX

PS Claim 1; SEQ ID NO 4; 42pp; English.

XX

CC The invention relates to interleukin-1 zeta polypeptide and
CC polynucleotide. The agonist or antagonist of the interleukin-1 zeta is
CC useful in modulating a cell that is involved in inflammatory response.
CC The peptide fragments of IL-1 zeta are useful in research and diagnostic
CC tools in the study of inflammatory reactions to antigenic challenge and
CC the development of more effective anti-inflammatory therapeutics.
CC Interleukin-1 zeta is useful in regulation and/or development of immune
CC system. A polynucleotide encoding IL-1 zeta is useful for detecting the
CC expression level of the polypeptide in a patient suspected of having an
CC immunological disorder. The present sequence is a human interleukin-1
CC zeta variant.

XX

SQ Sequence 218 AA;

Query Match 100.0%; Score 1165; DB 8; Length 218;
Best Local Similarity 100.0%; Pred. No. 2.2e-117;
Matches 218; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSFVGENSEGVKMGSEDEKDEPQCCELDPAVSPLEPGPSLPAMNFVHTSPKVKNLNPKKF 60

Db 1 MSFVGENSEGVKMGSEDEKDEPQCCELDPAVSPLEPGPSLPAMNFVHTSPKVKNLNPKKF 60

Qy 61 SIHDQDHKVLVLDGSLNLIAPDKNYIRPEIFFALASSLSSASAEKGSPIILLGVSKGEFCL 120

|||||

Db 61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120

Qy 121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAHPGWFICTS 180
|||||

Db 121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAHPGWFICTS 180

Qy 181 CNCNEPVGVTDFENRKHIEFSFQPVCKAEMSPSEVSD 218
|||||

Db 181 CNCNEPVGVTDFENRKHIEFSFQPVCKAEMSPSEVSD 218

RESULT 8

AAAY95299

ID AAY95299 standard; protein; 218 AA.

XX

AC AAY95299;

XX

DT 12-SEP-2000 (first entry)

XX

DE Human interleukin-1 zeta splice variant TDZ.1.

XX

KW Interleukin-1 zeta; IL-1 zeta; splice variant; human; TDZ.1;

KW testis-derived zeta variant; therapy; inflammation; fever.

XX

OS Homo sapiens.

XX

PN WO200036108-A2.

XX

PD 22-JUN-2000.

XX

PF 14-DEC-1999; 99WO-US029549.

XX

PR 14-DEC-1998; 98US-0112163P.

PR 10-NOV-1999; 99US-0164675P.

XX

PA (IMMV) IMMUNEX CORP.

XX

PI Sims JE, Smith DE, Born TL;

XX

DR WPI; 2000-442387/38.

DR N-PSDB; AAA27920.

XX

PT Isolated interleukin-1 (IL-1) zeta nucleic acids and splice variants

PT TDZ1, TDZ2, TDZ3 and their encoding proteins, useful as probes for

PT identifying genes associated with diseases such as glaucoma, and insulin-

PT dependent diabetes mellitus.

XX

PS Claim 10; Page 11; 87pp; English.

XX

CC The present sequence is that of splice variant TDZ.1 (testis-derived zeta

CC variant) of human interleukin-1 zeta (IL-1 zeta). TDZ.1 mRNA is generated

CC from exons 1, 2, 4, 5 and 6 of the IL-1 zeta locus, and the encoded

CC protein is probably a functional IL-1 like molecule. TDZ.1 mRNA is

CC expressed most strongly in the kidney, skeletal muscle, testis, prostate,

CC ovary, colon, small intestine, liver, placenta, lung, tonsil, foetal

CC liver, lymph node and bone marrow. The invention is directed to novel,

CC purified and isolated IL-1 zeta, its splice variants and Xrec2

CC polypeptides (see AAY95297-301), the nucleic acids (see AAA27918-22)

CC encoding such polypeptides, processes for production of recombinant forms

CC of such polypeptides, and their uses. The polypeptides can be used to

CC study cellular processes such as immune regulation, cell proliferation,

CC cell death, cell migration, cell-to-cell interaction and inflammatory

CC responses, to identify proteins associated with IL-1 zeta, to screen for

CC potential inhibitors, and to prepare antibodies. In particular, they can

CC be used to activate and/or inhibit the activation of vascular endothelial

CC cells and lymphocytes, induce and/or inhibit the induction of local
CC tissue destruction and fever, inhibit and/or stimulate macrophages and
CC vascular endothelial cells to produce IL-6, induce and/or inhibit the
CC induction of prostaglandins, nitric oxide synthetase, and
CC metalloproteases, and upregulate and/or inhibit the upregulation of
CC molecules on the surface of vascular endothelial cells
XX
SQ Sequence 218 AA;

Query Match 99.7%; Score 1161; DB 3; Length 218;
Best Local Similarity 99.5%; Pred. No. 5.9e-117;
Matches 217; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy	1	MSFVGENSGVKMGSEDEWEKDEPQCCLLEDPAVSPLEPGPSLPAMNFVHTSPKVKNLNPKKF	60
Db	1	MSFVGENSGVKMGSEDEWEKDEPQCCLLEDPAVSPLEPGPSLPMTNFVHTSPKVKNLNPKKF	60
Qy	61	SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSASAEEKGSPILLGVSKGEFCL	120
Db	61	SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSASAEEKGSPILLGVSKGEFCL	120
Qy	121	YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS	180
Db	121	YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS	180
Qy	181	CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD	218
Db	181	CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD	218

AA70927

ID AAY70927 standard; protein; 218 AA.

AC AAY70927;

DT 05-SEP-2000 (first entry)

DE Human zilla4 protein.

KW Human interleukin-1; IL-1; zilla4 protein; inflammation; arthritis;
KW psoriasis; septic shock; graft-versus-host disease; leukaemia; cancer;
KW anaemia; inflammatory bowel disease; acute neuropathology; shock;
KW chronic neuropathology; respiratory disease syndrome; restenosis;
KW acquired immune deficiency syndrome; AIDS; antiinflammatory; cytostatic;
KW anti-arthritic; anti-psoriatic; antibacterial; immunosuppressive;
KW anti-anaemic; neuroprotective; vasotropic;
KW anti-human immunodeficiency virus; HIV.

OS Homo sapiens.

Key	Location/Qualifiers
FT Domain	60. .64
FT	/label= Beta_strand
FT Domain	65. .67
FT	/note= "Variable loop region involved in receptor binding"
FT Domain	68. .72
FT	/label= Beta_strand
FT Domain	73. .76
FT	/note= "Variable loop region involved in receptor binding"
FT Domain	77. .79
FT	/label= Beta_strand
FT Domain	80. .89

```

FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  90. .96
FT          /label= Beta_strand
FT  Domain  97. .107
FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  108. .113
FT          /label= Beta_strand
FT  Domain  114. .117
FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  118. .123
FT          /label= Beta_strand
FT  Domain  124. .131
FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  132. .138
FT          /label= Beta_strand
FT  Domain  139. .153
FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  154. .160
FT          /label= Beta_strand
FT  Domain  161. .164
FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  165. .169
FT          /label= Beta_strand
FT  Domain  170. .174
FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  175. .179
FT          /label= Beta_strand
FT  Domain  180. .186
FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  187. .189
FT          /label= Beta_strand
FT  Domain  190. .200
FT          /note= "Variable loop region involved in receptor
FT          binding"
FT  Domain  201. .204
FT          /label= Beta_strand
XX
PN  WO200024899-A2.
XX
PD  04-MAY-2000.
XX
PF  27-OCT-1999;   99WO-US025038.
XX
PR  27-OCT-1998;   98US-00179614.
XX
PA  (ZYMO ) ZYMOGENETICS INC.
XX
PI  West RR,  Sheppard PO,  Gao Z;
XX
DR  WPI; 2000-350740/30.
DR  N-PSDB; AAD00210.
XX
PT  Immunomodulatory interleukin-1 homolog zilla4 proteins, useful for
PT  treatment of e.g. arthritis, psoriasis, septic shock, graft-versus-host
PT  disease, leukemia.
XX
PS  Claim 4; Fig 2; 88pp; English.

```

XX
CC The present sequence is the human interleukin (IL)-1 homolog zilla4
CC protein. This protein contains a core structure of 12 beta-strands wound
CC into a beta-barrel, with the beta-stands seperated from each other by
CC loops. The loops between these beta-strands are highly variable among the
CC family members and are believed to be involved in receptor binding. The
CC zilla4 proteins modulate inflammation and other immunological processes
CC and are therefore useful for treatment of arthritis, psoriasis, septic
CC shock, graft-versus-host disease and leukaemia. Other diseases that may
CC be modulated by zilla4 proteins include cancer, anaemia, inflammatory
CC bowel disease, acute and chronic neuropathologies, shock, respiratory
CC disease syndrome, restenosis and acquired immune deficiency syndrome
XX
SQ Sequence 218 AA;

Query Match 99.1%; Score 1154; DB 3; Length 218;
Best Local Similarity 99.1%; Pred. No. 3.4e-116;
Matches 216; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 MSFVGENSGVKMGSEDWEKDEPQCCELDPAVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60
|
Db 1 MSFVGENSGVKMGSEDWEKDEPQCCELDPAVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60

Qy 61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120
|
Db 61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120

Qy 121 YCDKDKGQSHPSLQLKKEKLMKLAQKESARRPFIFYRAQVGSWNMLESAHPGWFICTS 180
|
Db 121 YCDKDKGQSHPSLQLKKEKLMKLAQKESARRPFIFYRAQVGSWNMLESAHPGWFICTS 180

Qy 181 CNCNEPVGVTDFENRKHIEFSFQPVCKAEMSPSEVSD 218
|
Db 181 CNCNEPVGVTDFENRKHIEFSFQPVCKAEMSPSEVSD 218

RESULT 10

AAAY96940

ID AAY96940 standard; protein; 218 AA.

XX

AC AAY96940;

XX

DT 31-OCT-2000 (first entry)

XX

DE Human IL-1 receptor antagonist 1 V.

XX

KW hIL-1Ra1V; human interleukin-1 receptor antagonist-1; IL-11p;
KW osteopathic; interleukin-1-like polypeptide; anti-inflammatory;
KW anti-asthmatic; anti-arthritis; antimicrobial; respiratory; vaccine;
KW anti-ischemic; dermatological; immunomodulatory; gastrointestinal;
KW gene therapy.

XX

OS Homo sapiens.

XX

PN WO200039297-A2.

XX

PD 06-JUL-2000.

XX

PF 22-DEC-1999; 99WO-US030720.

XX

PR 23-DEC-1998; 98US-0113430P.

PR 22-JAN-1999; 99US-0116843P.

PR 13-APR-1999; 99US-0129122P.

XX

PA (GETH) GENENTECH INC.

XX
PI Goddard A, Pan J;
XX
DR WPI; 2000-452395/39.
DR N-PSDB; AAA51604.
XX
PT Nucleic acids encoding interleukin-1-like polypeptides, useful for
PT preventing and treating e.g. inflammation, asthma and psoriasis.
XX
PS Claim 22; Fig 19; 143pp; English.
XX
CC An isolated nucleic acid molecule encoding an interleukin-1-like
CC polypeptide (IL-1lp) that retains one or more activities of the peptide
CC from which it is derived, such as the IL-18R binding activity of a human
CC interleukin-1 receptor antagonist-1 (hIL-1Ra1) polypeptide, is new. The
CC nucleic acids may be used in molecular engineering applications, e.g.
CC hybridization assays and chromosome and gene mapping studies, for
CC recombinantly producing the IL-1lp polypeptide or for producing gene
CC knock out animals to study the role of the protein in metabolism and
CC disease processes (conversely, gene therapy protocols may be used to
CC supplement a patients production of the polypeptide or to rectify
CC mutations that lead to the production of in active peptides). The
CC peptides produced may be used to screen for and produce modulators (e.g.
CC antibodies) of IL-1lp protein expression and activity which may be use to
CC treat disorders associated with inappropriate IL-1lp expression and
CC activity, such as inflammatory disorders, asthma, arthritis,
CC osteoarthritis, sepsis, acute lung injury, adult respiratory distress
CC syndrome, idiopathic pulmonary fibrosis, ischemic reperfusion disease,
CC psoriasis, graft versus host disease and/or inflammatory bowel disease
XX
SQ Sequence 218 AA;

Query Match 99.1%; Score 1154; DB 3; Length 218;
Best Local Similarity 99.1%; Pred. No. 3.4e-116;
Matches 216; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 MSFVGENSGVKMGSEDWEKDEPQCCLDPVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60
|
Db 1 MSFVGENSGVKMGSEDWEKDEPQCCLDPAGSPLEPGPSLPTMNFVHTSPKVKNLNPCKF 60

Qy 61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120
|
Db 61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120

Qy 121 YCDKDKGQSHPSLQLKKEKLMKLAQKESARRPFIFYRAQVGSWNMLESAHPGWFICT 180
|
Db 121 YCDKDKGQSHPSLQLKKEKLMKLAQKESARRPFIFYRAQVGSWNMLESAHPGWFICT 180

Qy 181 CNCNEPVGVTDFKFNKRKHIEFSFQPVCKAEMSPSEVSD 218
|
Db 181 CNCNEPVGVTDFKFNKRKHIEFSFQPVCKAEMSPSEVSD 218

RESULT 11

AAB28266

ID AAB28266 standard; protein; 218 AA.

XX

AC AAB28266;

XX

DT 13-FEB-2001 (first entry)

XX

DE Human interleukin-1 homologue IL-1H4.

XX

KW Human; interleukin-1 homologue; IL-1H4; inflammation; septicaemia;
KW autoimmune disease; inflammatory bowel disease; psoriasis; arthritis;

KW transplant rejection; graft versus host disease; infection; stroke;
KW ischaemia; acute respiratory disease; allergy; asthma; restenosis;
KW brain injury; AIDS; bone disease; osteoporosis; cancer;
KW congestive heart failure; atherosclerosis; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN WO200063226-A1.
XX
PD 26-OCT-2000.
XX
PF 14-APR-2000; 2000WO-US010207.
XX
PR 16-APR-1999; 99US-00293625.
XX
PA (SMIK). SMITHKLINE BEECHAM CORP.
XX
PI Young PR, Mcdonnell PC;
XX
DR WPI; 2000-687155/67.
DR N-PSDB; AAC66727.
XX
PT Interleukin-1 homolog useful for treating conditions such as chronic and
PT acute inflammation, septicemia, autoimmune diseases ischemia, acute
PT respiratory disease, allergies, and asthma.
XX
PS Claim 1; Page 28-29; 30pp; English.
XX
CC The present sequence is human interleukin-1 homologue (IL-1H4). IL-1H4 is
CC useful for treating conditions such as chronic and acute inflammation,
CC septicaemia, autoimmune diseases (e.g. inflammatory bowel disease,
CC psoriasis, and arthritis), transplant rejection, graft versus host
CC disease, infection, stroke, ischaemia, acute respiratory disease,
CC allergies, asthma, restenosis, brain injury, AIDS, bone diseases (e.g.
CC osteoporosis), cancer, congestive heart failure, atherosclerosis, and
CC Alzheimer's disease, related to either an excess of, or an under-
CC expression of, IL-1H4 polypeptide activity
XX
SQ Sequence 218 AA;

Query Match 99.1%; Score 1154; DB 3; Length 218;
Best Local Similarity 99.1%; Pred. No. 3.4e-116;
Matches 216; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy      1 MSFVGENSEGVKMGSEDWEKDEPQCCLLEDPVSPLEPGPSLPAMNFBVHTSPKVKNLNPKKF 60
          |||
Db      1 MSFVGENSEGVKMGSEDWEKDEPQCCLLEDPAGSPLEPGPSLPTMNFVHTSPKVKNLNPKKF 60

Qy     61 SIHDQDQDKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGKSPILLGVSKGEFCL 120
          |||
Db     61 SIHDQDQDKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGKSPILLGVSKGEFCL 120

Qy    121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS 180
          |||
Db    121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS 180

Qy    181 CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD 218
          |||
Db    181 CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD 218
```

RESULT 12

AAB85136

ID AAB85136 standard; protein; 218 AA.

XX


```
Qy      61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEGSPILLGVSKGEFCL 120

Qy     121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS 180
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS 180

Qy     181 CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD 218
        ||||||||||||||||||||||||||||||||||||
Db     181 CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD 218
```

RESULT 13

ADN05012

ID ADN05012 standard; protein; 218 AA.

XX

AC ADN05012;

XX

DT 01-JUL-2004 (first entry)

XX

DE Antipsoriatic protein sequence #686.

XX

KW antipsoriatic; gene therapy; psoriasis; diagnosis.

XX

OS Homo sapiens.

XX

PN WO2004028479-A2.

XX

PD 08-APR-2004.

XX

PF 25-SEP-2003; 2003WO-US030907.

XX

PR 25-SEP-2002; 2002US-0414006P.

XX

PA (GETH) GENENTECH INC.

XX

PI Bodary S, Clark H, Jackman J, Schoenfeld J, Williams PM, Wood WI;

PI Wu TD;

XX

DR WPI; 2004-305105/28.

DR N-PSDB; ADN05011.

XX

PT New PRO nucleic acid or polypeptide, useful for preparing a
PT pharmaceutical composition for diagnosing or treating psoriasis in a
PT mammal.

XX

PS Claim 9; SEQ ID NO 1406; 3069pp; English.

XX

CC The invention relates to novel polynucleotide and polypeptides for
CC treating psoriasis or a sequence having at least 80% identity to the
CC above sequences. The nucleic acid is useful for preparing a composition
CC for diagnosing or treating psoriasis in a mammal. This sequence
CC corresponds to one of the polypeptides of the invention.

XX

SQ Sequence 218 AA;

Query Match 99.1%; Score 1154; DB 8; Length 218;
Best Local Similarity 99.1%; Pred. No. 3.4e-116;
Matches 216; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy      1 MSFVGENSGVKMGSEDWEKDEPQCCLDPVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MSFVGENSGVKMGSEDWEKDEPQCCLDPAGSPLEPGPSLPTMNFVHTSPKVKNLNPCKF 60
```

http://es/ScoreAccessWeb/GetItem.action?AppId=10679201&seqId=512138&ItemName=us-10-679-201... 5/12/2006

CC sequence shown in figure-2 (AAY70927)

XX

SQ Sequence 218 AA;

Query Match 98.8%; Score 1151; DB 3; Length 218;
 Best Local Similarity 98.6%; Pred. No. 7.2e-116;
 Matches 215; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 MSFVGENSGVKMGSEDWEKDEPQCCELEDAVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60
 |||
 Db 1 MSFVGENSGVKMGSEDWEKDEPQCCELEDAVSPLEPGPSLPAMNFVHTSPKVKNLNPCKF 60

Qy 61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEKGSPIILLGVSKGEFCL 120
 |||
 Db 61 SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEKGSPIILLGVSKGEFCL 120

Qy 121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS 180
 |||
 Db 121 YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTS 180

Qy 181 CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD 218
 |||
 Db 181 CNCNEPVGVTDKFENRKHIDFSFQPVCKAEMSPSEVSD 218

RESULT 15

ADH89067

ID ADH89067 standard; protein; 218 AA.

XX

AC ADH89067;

XX

DT 22-APR-2004 (first entry)

XX

DE Human zilla4 polypeptide.

XX

KW Human; interleukin-1 homologue; IL-1; zilla4; immune response;

KW inflammatory disease; cancer; anaemia; immunomodulator; antiinflammatory;

KW cytostatic; antianaemic.

XX

OS Homo sapiens.

XX

PN US2003148467-A1.

XX

PD 07-AUG-2003.

XX

PF 22-NOV-2002; 2002US-00302554.

XX

PR 27-OCT-1998; 98US-0105824P.

PR 27-OCT-1999; 99US-00428118.

XX

PA (ZYMO) ZYMOGENETICS INC.

XX

PI West RR, Sheppard PO, Gao Z;

XX

DR WPI; 2003-897576/82.

DR N-PSDB; ADH89066.

XX

PT New interleukin-1 homolog Zilla4 protein, useful for modulating an immune
 PT response and for treating diseases, e.g., inflammatory diseases, cancer
 PT or anemia.

XX

PS Claim 8; SEQ ID NO 2; 44pp; English.

XX

CC The present invention relates to the isolation of human interleukin-1 (IL
 CC -1) homologues designated zilla4, and the polynucleotide sequences that

CC encode them. The gene encoding human zilla4 is located on chromosome 2.
CC Also disclosed is a method of making these proteins and a method of
CC modulating an immune response. The proteins are useful for treating
CC diseases such as inflammatory diseases, cancer, and anaemia. The present
CC sequence represents human zilla4.
XX
SQ Sequence 218 AA;

Query Match 98.8%; Score 1151; DB 7; Length 218;
Best Local Similarity 98.6%; Pred. No. 7.2e-116;
Matches 215; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy	1	MSFVGENSGVKMGSEDWEKDEPQC	LEDPAVSPLEPGPSLPAMNFVHTSPKVKNLNP	KKF	60
Db	1	MSFVGENSGVKMGSEDWEKDEPQC	LEDPAGSPLEPGPSLPTMNFVHTSPKVKNLNP	KKF	60
Qy	61	SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASA	EKGSPILLGVSKGEFCL		120
Db	61	SIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASA	EKGSPILLGVSKGEFCL		120
Qy	121	YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESA	AHPGWFICTS		180
Db	121	YCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLQSA	AHPGWFICTS		180
Qy	181	CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD			218
Db	181	CNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD			218

Search completed: May 11, 2006, 22:03:42
Job time : 189 secs